APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
+7.92%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$3.7B
AUM Growth
+$3.7B
(+3.2%)
Cap. Flow
+$51.7M
Cap. Flow
% of AUM
1.4%
Top 10 Holdings %
Top 10 Hldgs %
34.9%
Holding
146
New
53
Increased
24
Reduced
24
Closed
34
Top Buys
| 1 |
Eli Lilly
LLY
|
$130M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$129M |
| 3 |
Hologic
HOLX
|
$80.7M |
| 4 |
Biogen
BIIB
|
$63.7M |
| 5 |
NeoGenomics
NEO
|
$61.7M |
Top Sells
| 1 |
AstraZeneca
AZN
|
$182M |
| 2 |
Intuitive Surgical
ISRG
|
$103M |
| 3 |
AbbVie
ABBV
|
$66.8M |
| 4 |
Avantor
AVTR
|
$64.1M |
| 5 |
Medtronic
MDT
|
$60.7M |
Sector Composition
| 1 | Healthcare | 95.4% |
| 2 | Technology | 1.61% |
| 3 | Financials | 0.67% |
| 4 | Consumer Discretionary | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vertex Pharmaceuticals
VRTX
$100B
| $192M | 5.18% | 950,000 +639,100 | +206% | +$129M |
|
|
2
AbbVie
ABBV
$372B
| $167M | 4.52% | 1,484,400 -592,800 | -29% | -$66.8M |
|
3
Arvinas
ARVN
$568M
| $143M | 3.86% | 1,854,000 +93,700 | +5% | +$7.21M |
|
|
4
Eli Lilly
LLY
$657B
| $130M | 3.51% | +565,500 | New | +$130M |
|
5
Maravai LifeSciences
MRVI
$350M
| $124M | 3.34% | 2,963,545 +202,000 | +7% | +$8.43M |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $122M | 3.29% | 753,000 +277,300 | +58% | +$44.8M |
|
7
Zentalis Pharmaceuticals
ZNTL
$122M
| $115M | 3.11% | 2,160,000 +896,700 | +71% | +$47.7M |
|
|
8
Avantor
AVTR
$9.18B
| $113M | 3.05% | 3,180,000 -1,805,100 | -36% | -$64.1M |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $101M | 2.73% | 640,000 +62,100 | +11% | +$9.8M |
|
|
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $85.7M | 2.32% | 882,500 -167,300 | -16% | -$16.2M |
|
|
11
Hologic
HOLX
$14.9B
| $80.7M | 2.18% | +1,208,800 | New | +$80.7M |
|
12
Syndax Pharmaceuticals
SNDX
$1.41B
| $79.2M | 2.14% | 4,615,000 +769,000 | +20% | +$13.2M |
|
13
ESSA Pharma
EPIX
$11.4M
| $78.6M | 2.12% | 2,750,000 -90,000 | -3% | -$2.57M |
|
14
Exact Sciences
EXAS
$8.98B
| $73.3M | 1.98% | 590,000 -8,000 | -1% | -$994K |
|
|
15
Medtronic
MDT
$119B
| $66.4M | 1.79% | 535,000 -489,200 | -48% | -$60.7M |
|
16
Neurocrine Biosciences
NBIX
$13.8B
| $66.3M | 1.79% | 681,000 +159,600 | +31% | +$15.5M |
|
17
Nuvation Bio
NUVB
$1.02B
| $64.9M | 1.75% | 6,966,376 -555,565 | -7% | -$5.17M |
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $64.3M | 1.74% | 943,000 +44,450 | +5% | +$3.03M |
|
|
19
Biogen
BIIB
$19.4B
| $63.7M | 1.72% | +183,900 | New | +$63.7M |
|
|
20
NeoGenomics
NEO
$1.13B
| $61.7M | 1.67% | +1,367,000 | New | +$61.7M |
|
21
Intellia Therapeutics
NTLA
$1.22B
| $61.5M | 1.66% | +380,000 | New | +$61.5M |
|
|
IMAB
22
I-MAB
IMAB
$340M
| $61.2M | 1.65% | 729,000 -600,000 | -45% | -$50.4M |
|
|
CTLT
23
DELISTED
CATALENT, INC.
CTLT
| $58.4M | 1.58% | 540,000 -20,000 | -4% | -$2.16M |
|
24
Shattuck Labs
STTK
$47M
| $56.2M | 1.52% | 1,940,200 +609,815 | +46% | +$17.7M |
|
25
Centene
CNC
$14.3B
| $54.8M | 1.48% | +751,200 | New | +$54.8M |
|